Special Issue

Genetic and Genomic Biomarkers in Cancer Diagnosis, Prognosis, and Treatment Prediction

Message from the Guest Editor

Advances in cancer genetics and genomics are expanding the opportunities for utilizing genetic and genomic biomarkers in cancer diagnosis, prognosis. and treatment prediction. Cancer genetic and genomic tests typically analyze nucleic acid-based biomarkers and can be categorized based on their medical applications: diagnostic, prognostic, and predictive. Cancer diagnostic tests are used for cancer screening, diagnosis, subtyping, and staging. Prognostic tests provide insights into the natural progression of cancer and potential outcomes. In contrast, predictive tests offer information about how likely a patient is to respond to a specific drug or therapy. Importantly, genetic and genomic test is expected to have an ever-increasing impact on oncology. For instance, biomarkers can help select patients who are likely to benefit from targeted therapies, monitor treatment resistance, assess recurrence risk, and identify pharmacogenetic risks for adverse drug reactions. I encourage basic and preclinical researchers to present original research articles and reviews, emphasizing the current mechanisms and preclinical advancement of laboratory genetics and genomics in oncology.

Guest Editor

Prof. Dr. Jianli Dong

Department of Pathology, Sealy Center for Cancer Cell Biology, University of Texas Medical Branch, 5.202 John Sealy Annex, 301 University Boulevard, Galveston, TX 77555, USA

Deadline for manuscript submissions

31 July 2025



Biomolecules

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 9.2
Indexed in PubMed



mdpi.com/si/227650

Biomolecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomolecules@mdpi.com

mdpi.com/journal/biomolecules





Biomolecules

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 9.2 Indexed in PubMed



About the Journal

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in Biomolecules so far. We would be delighted to welcome you as one of our authors.

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3C, DK-2200 Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer Science, Virginia Commonwealth University, Richmond, VA 23284, USA

Author Benefits

Open Access

 free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)

